Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZH9 in Non-Muscle Invasive Bladder Cancer
NCT06181266Phase 1Completed
- Sponsor
- Prokarium
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, double-blind trial of M01ZH09 in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Prokarium. Primary endpoint: Incidence of dose-limiting toxicities at 28 days. Started Jan 2024; status: completed.
02
Drugs
M01ZH09
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06181266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181266.